The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of nab-paclitaxel (nab-P)–based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2.
 
Ajeet Gajra
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene
Research Funding - Celgene; Merck
Travel, Accommodations, Expenses - Celgene
 
Nagla Abdel Karim
No Relationships to Disclose
 
Deborah A. Mulford
No Relationships to Disclose
 
Liza Cosca Villaruz
No Relationships to Disclose
 
Marc Ryan Matrana
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; Merck
 
Haythem Y. Ali
No Relationships to Disclose
 
Edgardo S. Santos
Speakers' Bureau - Amgen; Boehringer Ingelheim; Celgene; Genentech; Lilly; Millennium; Pfizer
 
Teng Jin Ong
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
Alexandra Sanford
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
Katayoun Amiri
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
David R. Spigel
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)